虚拟直肠间隔物辅助前列腺癌放疗中植入式直肠间隔物决策:剂量、毒性与成本效果比较
本研究基于16例前列腺癌患者(8例直肠球囊植入、8例水凝胶间隔物)的CT扫描,构建虚拟直肠间隔物(V-IRS)并与实际IRS比较剂量、毒性和成本效果。V-IRS与IRS对直肠V75的改善平均分别为4.3%和4.2%,NTCP最大降低分别为3.9%和4.0%,成本效果分类准确率达100%。V-IRS结合毒性预测模型和成本效果分析有望成为植入决策支持工具。
要点
- V-IRS与IRS对直肠V75改善和NTCP降低程度相近。
- RBI对1/8患者具成本效果,水凝胶对2/8有效、1例接近有效。
- V-IRS模型对成本效果分类准确率为100%。
核心结论
- V-IRS结合毒性预测模型和成本效果分析是植入水凝胶或直肠球囊间隔物决策支持工具的有前景基础。
研究设计与样本
- 在16例患者中测试V-IRS:8例直肠球囊植入(RBI),8例水凝胶间隔物。
- V-IRS基于7例RBI患者的CT扫描开发,使用IRS植入前后的CT扫描进行验证。
- 基于IRS前、IRS后和V-IRS的CT扫描制定IMRT计划,处方剂量70 Gy至计划靶区。
- 毒性采用外部验证的正常组织并发症概率(NTCP)模型评估,成本效果采用已发表的Markov模型分析。
主要发现
- 直肠V75(接受75Gy的直肠体积)在IRS和V-IRS下平均分别改善4.2%和4.3%。
- IRS和V-IRS导致的最大NTCP降低分别为4.0%和3.9%。
- RBI对1/8患者具成本效果,水凝胶对2/8患者有效,对第3例接近有效。
- 模型关于成本效果的分类准确率为100%。
关键数值与推荐
- 直肠V75在IRS和V-IRS下平均分别改善4.2%和4.3%。
- IRS和V-IRS的最大NTCP降低分别为4.0%和3.9%。
- RBI对1/8患者具成本效果,水凝胶对2/8患者有效、对1例接近有效。
- 成本效果分类准确率为100%。
临床怎么用
- V-IRS可用于辅助识别植入IRS具有成本效果的前列腺癌放疗患者。
- 结合NTCP模型和成本效果分析,V-IRS有望支持水凝胶或直肠球囊间隔物的个体化植入决策。
局限性
- V-IRS仅在16例患者中测试,样本量有限。
- V-IRS基于7例RBI患者的CT扫描开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Previous studies have shown that the implantable rectum spacer (IRS) is not beneficial for all patients. A virtual IRS (V-IRS) was constructed to help identify the patients for whom it is cost-effective to implant an IRS, and its viability as a tool to tailor the decision of an IRS implantation to be beneficial for the specified patient was assessed. Please watch animation: (https://www.youtube.com/watch?v=tDlagSXMKqw) MATERIALS AND METHODS: The V-IRS was tested on 16 patients: 8 with a rectal balloon implant (RBI) and 8 with a hydrogel spacer. A V-IRS was developed using 7 computed tomography (CT) scans of patients with a RBI. To examine the V-IRS, CT scans before and after the implantation of an IRS were used. IMRT plans were made based on CT scans before the IRS, after IRS and with the V-IRS, prescribing 70 Gray (Gy) to the planning target volume. Toxicity was accessed using externally validated normal tissue complication probability (NTCP) models, and the Cost-effectiveness was analyzed using a published Markov model. RESULTS: The rectum volume receiving 75Gy (V75) were improved by both the IRS and the V-IRS with on average 4.2% and 4.3% respectively. The largest NTCP reduction resulting from the IRS and the V-IRS was 4.0% and 3.9% respectively. The RBI was cost-effective for 1 out of 8 patients, and the hydrogel was effective for 2 out of 8 patients, and close to effective for a third patient. The classification accuracy of the model, regarding cost-effectiveness, was 100%. CONCLUSION: The V-IRS approach in combination with a toxicity prediction model and a cost-effectiveness analyses is a promising basis for a decision support tool for the implantation of either a hydrogel spacer or a rectum balloon implant.
引用
- van Wijk Y, Vanneste BGL, Walsh S, et al. Development of a virtual spacer to support the decision for the placement of an implantable rectum spacer for prostate cancer radiotherapy: Comparison of dose, toxicity and cost-effectiveness. Radiother Oncol. 2017. PMID: 28823404. doi:10.1016/j.radonc.2017.07.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。